More than 200 million people worldwide suffer from peripheral arterial disease (PAD).1,2
Contraindication of contrast media makes it challenging to diagnose a large number of these patients.
Overcome these current limitations and enhance your clinical capabilities with QISS, a completely new non-contrast MR Angiography technique.
Planning and execution of CE-MRA requires a high degree of expertise to prevent venous inflow and other artifacts, caused by suboptimal timing of contrast media injection, for example.
With Set-n-go implementation, "QISS provides an easy-to-handle approach for imaging peripheral arteries with little requirements for further adjustments".3 Additionally, QISS offers the potential to save operational costs of up to $180 / patient by omitting disposables, contrast agent and lab tests (GFR).4
The software package for non-contrast enhanced peripheral MR Angiography is based on quiescent interval single-shot imaging.
About 347 million people worldwide have diabetes.5 In many cases this leads to perihperal artery disease.
"The high prevalance of chronic renal impairment in diabetic patients with PAD and the need for high doses of gadolinium based contrast agents place them at risk for nephrogenic system fibrosis."6
QISS provides an accurate non-contrast alternative to CE-MRA for demonstrating clinically significant arterial disease in patients where contrast agents are contraindicated.6,7 Enhance clinical capabilities with access to latest clinical standards of care with the reduced need for CE-MRA.
"QISS MRA should become the non-contrast MRA technique of choice in patients with renal dysfunction."8
Maria Carr, Research Technologist
Northwestern University Feinberg School of Medicine
Chicago, US
syngo MR E11
Additional technical prerequisites may apply. Upon receiving your request, your local Siemens representative will clarify whether your system meets the requirements.
